Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
about
Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.HIV entry inhibitors and their potential in HIV therapyInsights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.Recent patents regarding the discovery of small molecule CXCR4 antagonists.Novel compounds for the treatment of HIV type-1 infection.Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.CXCR4-based imaging agents.Development of novel CXCR4-based therapeutics.The successes and failures of HIV drug discovery.Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors.Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.Preclinical discovery and development of maraviroc for the treatment of HIV.Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.Discovery of novel N-aryl piperazine CXCR4 antagonists.A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner.Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.Emerging antiviral drugsUpdate on the development of HIV entry inhibitors
P2860
Q33565687-F72CD95F-5717-4FF9-B6D1-8C11AEC9EF37Q34595921-3701FE64-262C-4F19-B4FB-5BFF7021FEE7Q35168976-123AA728-7266-42B8-A6FE-69FB82D057BBQ35213463-0F85514F-C495-4D52-B099-CF287BCBD588Q35964652-F88BFB8A-35A1-4BC9-95AB-E121C2D3136AQ36249853-BE55086F-0A18-4DE3-B0DE-71A4EB27AE80Q36334083-2B9179F2-FDA0-49C6-8CF1-55DBC051104EQ36445393-20A4B8CF-DE19-4D27-8CE7-EB53FCFBA2FEQ36593820-C5E7734B-81C9-4A00-AA62-4EB51823B9B5Q37247686-C3056044-ED7B-4068-A325-383DDF595B19Q37351199-53990B39-52E5-45BE-8E98-A6616E1632E4Q37481233-2C118FD2-31CA-42E2-9CC1-EB8B1E9E4DA1Q37502492-9965B313-3681-4A0F-B05E-ECC6CE9BAE3DQ37577890-7121E586-B710-470D-A3A2-0924711EA1A0Q37827167-4A89DF48-6C4B-42C6-9654-504E05A7AB1CQ37834097-861321EF-E66D-4A1F-8A45-DDA714F52BE2Q37866794-FFB90ACC-4E50-43F7-8275-CB208FF99BF7Q37951878-79B886D5-7815-4DA1-A152-E596EC5681B2Q37979306-DF6A0033-8CD9-400F-8341-190B068211BAQ38014557-3B0F9336-8BC8-4BB8-A295-538E2E0F6F4BQ38808628-16142BEC-A8FF-4FCB-B4E1-30355955A455Q38809938-4C0ABCED-EE92-4090-A00A-07E1EF0E15C8Q39174058-2D594271-8445-4FCA-B57F-032667498156Q39236911-575CC433-FDAE-4B0B-B734-3554CF5698C9Q39556338-96CA25CD-11B7-4E2B-8882-E13E8012EE68Q40686762-D858BF41-2AEB-42EF-801E-7D3E8474E678Q42144564-67A413A5-9316-4EF1-848E-7698F72628A9Q42217563-196AB33A-3ADA-4FA5-A333-C680FCB46669Q42803194-3222E378-F47F-471C-BFEF-75D02AD31684Q47850217-2DEDFD97-388D-4A21-B3F1-956658BE64F3Q56786308-2AC4ECCE-1161-4FF6-B8B5-435C2E89EBDCQ58388992-B770F8C2-C5C7-4C78-9480-6FB5CE12B5C3
P2860
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Multiple-dose escalation study ...... inhibitor, in human subjects.
@ast
Multiple-dose escalation study ...... inhibitor, in human subjects.
@en
type
label
Multiple-dose escalation study ...... inhibitor, in human subjects.
@ast
Multiple-dose escalation study ...... inhibitor, in human subjects.
@en
prefLabel
Multiple-dose escalation study ...... inhibitor, in human subjects.
@ast
Multiple-dose escalation study ...... inhibitor, in human subjects.
@en
P2093
P2860
P356
P1476
Multiple-dose escalation study ...... inhibitor, in human subjects.
@en
P2093
Beatrice Kallungal
Camlin Tierney
Charles Flexner
Christina Lalama
Craig W Hendrix
Gary B Calandra
Ilene P Wiggins
Jeanne Conley
Jeong-Gun Park
Karin L Klingman
P2860
P304
P356
10.1128/AAC.00013-07
P407
P577
2007-04-23T00:00:00Z